5-Year trial tests new drug for debilitating bowel disease
NCT ID NCT07185009
Summary
This large, late-stage study is testing whether an investigational drug called duvakitug can help people with moderate-to-severe ulcerative colitis stay in remission. About 671 participants who responded to initial treatment will receive either duvakitug or a placebo for 40 weeks, with an option to continue in a long-term extension study for up to 5.5 years total. The main goal is to see if the drug safely keeps the disease under control, reduces symptoms like bowel urgency and pain, and improves quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BVL Clinical Research - Site Number: 8400005
RECRUITINGLiberty, Missouri, 64068, United States
-
Clinical Research of Osceola - Site Number: 8400013
RECRUITINGKissimmee, Florida, 34741, United States
-
Delta Research Partners - Site Number: 8400087
RECRUITINGMonroe, Louisiana, 71291, United States
-
Royal Palm Clinical Research - Site Number: 8400065
RECRUITINGFort Myers, Florida, 33901, United States
-
Tyler Research Institute, LLC - Site Number: 8400095
RECRUITINGTyler, Texas, 75701, United States
Conditions
Explore the condition pages connected to this study.